Theralase Technologies Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	0.82	1.03	1.07	1.14	0.78
Revenue Growth (YoY)	-20.99%	-3.45%	-6.00%	45.85%	-15.98%
Cost of Revenue	0.31	0.48	0.51	0.51	0.47
Gross Profit	0.51	0.55	0.56	0.63	0.31
Selling, General & Admin	2.23	2.09	2.17	1.58	1.93
Research & Development	2.45	2.75	2.98	4.28	2.92
Operating Expenses	4.68	4.84	5.16	5.86	4.85
Operating Income	-4.18	-4.29	-4.59	-5.23	-4.54
Interest Expense	-0.04	-0.02	-0.03	-0.02	-0.01
Interest & Investment Income	0.08	0.07	0.05	0.03	0.02
Currency Exchange Gain (Loss)	0.02	-0.01	0	-0.03	-0.02
EBT Excluding Unusual Items	-4.12	-4.26	-4.57	-5.25	-4.54
Legal Settlements	-	-	-	0.01	0.13
Pretax Income	-4.12	-4.26	-4.57	-5.24	-4.41
Net Income	-4.12	-4.26	-4.57	-5.24	-4.41
Net Income to Common	-4.12	-4.26	-4.57	-5.24	-4.41
Shares Outstanding (Basic)	253	240	220	208	204
Shares Outstanding (Diluted)	258	240	220	208	204
Shares Change (YoY)	7.28%	9.14%	5.79%	1.79%	-
EPS (Basic)	-0.02	-0.02	-0.02	-0.03	-0.02
EPS (Diluted)	-0.02	-0.02	-0.02	-0.03	-0.02
Free Cash Flow	-3.33	-3.35	-4.11	-5.17	-4.13
Free Cash Flow Per Share	-0.01	-0.01	-0.02	-0.03	-0.02
Gross Margin	62.11%	53.61%	52.52%	55.17%	39.70%
Operating Margin	-511.39%	-414.96%	-429.25%	-459.48%	-581.77%
Profit Margin	-504.71%	-411.84%	-427.06%	-459.81%	-565.06%
Free Cash Flow Margin	-408.43%	-323.78%	-384.01%	-454.37%	-529.21%
EBITDA	-4	-4.11	-4.4	-4.99	-4.32
D&A For EBITDA	0.17	0.18	0.19	0.24	0.22
EBIT	-4.18	-4.29	-4.59	-5.23	-4.54
Advertising Expenses	-	0.03	0.02	0.02	0.05

Source: S&P Global Market Intelligence. Standard template. Financial Sources.